YGYing Gan

Ying Gan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Gan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Zhang

    Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Xiaofei Wang

    Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center National Research Center for Genitourinary Oncology Beijing China

    2 shared publications
  • Aolin Li

    Department of Urology Peking University First Hospital Beijing China

    1 shared publication
  • Chaojie Wang

    Henan University

    1 shared publication
  • Chenchen Huang

    Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center National Research Center for Genitourinary Oncology Beijing China

    1 shared publication
  • Congcong Cao

    Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University Shenzhen China

    1 shared publication

Latest Publications

  • Open Access

    Single‐Cell Sequencing Reveals That CD4+ T Cells Eliminate Senescent Prostate Epithelium to Delay Progression of Benign Prostatic Hyperplasia

    by Zheng Li, Xiaofei Wang, Zhifu Liu, Senmao Li, Zhenan Zhang, Chenchen Huang, Yixiao Liu, Xingxing Tang, Jiaen Zhang, Peimin Zhou, et al.

    Benign prostatic hyperplasia (BPH) is an age‐related condition characterized by progressive prostate enlargement driven in part by the accumulation of senescent epithelial cells and their pro‐inflammatory secretome. Using human single‐cell RNA sequencing and laser capture microdissection, we identified C‐X‐C Motif Chemokine Ligand 13 (CXCL13) as a key chemokine secreted by senescent prostate epithelial cells. CXCL13 recruits CD4+ T cells via the C‐X‐C Chemokine Receptor Type 5 (CXCR5) receptor, facilitating immune recognition through human leukocyte antigen–DR isotype (HLA‐DR) and promoting senescent cell clearance. Functional assays revealed that CD4+ cytotoxic T lymphocytes (CTLs) mediate this clearance, while regulatory T cells (Tregs) suppress it, forming a functional dichotomy. Immunohistochemistry, transwell migration, and co‐culture assays confirmed this CXCL13–CXCR5–HLA‐DR axis. In a testosterone‐induced BPH mouse model, CXCL13 treatment enhanced CD4+ T cell infiltration and reduced epithelial senescence, while CD4+ T cell depletion reversed these effects. Single‐cell transcriptomics in mice further validated increased CXCL13 expression and CD4+ T cell engagement. These findings uncover a critical immune surveillance mechanism in BPH and suggest that targeting the CXCL13–CD4+ T cell axis may offer a novel therapeutic strategy for age‐related prostate enlargement.


  • Open Access

    ZNF677 suppresses renal cell carcinoma progression through N6‐methyladenosine and transcriptional repression of CDKN3

    by Aolin Li, Congcong Cao, Ying Gan, Xiaofei Wang, Tianyu Wu, Quan Zhang, Yuchen Liu, Lin Yao, Qian Zhang

    Background: Studies on biological functions of N6‐methyladenosine (m6A) modification in mRNA have sprung up in recent years. Previous studies have reported m6A can determine mRNA fate and play a pivotal role in tumour development and progression. The zinc finger protein 677 (ZNF677) belongs to the zinc finger protein family and possesses transcription factor activity by binding sequence‐specific DNA.Methods: The expression of ZNF677 and its clinicopathological impact were evaluated in renal cell carcinoma (RCC) patients. The m6A level of ZNF677 was determined by m6A methylated RNA immunoprecipitation‐sequencing (MeRIP‐seq) and MeRIP‐qPCR in RCC tissues and adjacent normal tissues. RNA immunoprecipitation‐qPCR (RIP‐qPCR) and luciferase assays were performed to identify the targeted effect of IGF2BP2 and YTHDF1 on ZNF677. RCC cells and subcutaneous models uncovered the role of ZNF677 methylated by CRISPR/dCas13b‐METTL3 in tumour growth. ZNF677‐binding sites in the CDKN3 promoter were investigated by chromatin immunoprecipitation (ChIP) and luciferase assays.Results: ZNF677 is frequently downregulated in RCC tissues and its low expression is associated with unfavourable prognosis and decreased m6A modification level. Further, we find the m6A‐modified coding sequence (CDS) of ZNF677 positively regulates its translation and mRNA stability via binding with YTHDF1 and IGF2BP2, respectively. Targeted specific methylation of ZNF677 m6A by CRISPR/dCas13b‐METLL3 system can significantly increase the m6A and expression level of ZNF677, and dramatically inhibit cell proliferation and induce cell apoptosis of RCC cells. In addition, ZNF677 exerted its tumour suppressor functions in RCC cells through transcriptional repression of CDKN3 via binding to its promoter. In vitro and clinical data confirm the negative roles of ZNF677/CDKN3 in tumour growth and progression of RCC.Conclusion: ZNF677 functions as a tumour suppressor and is frequently silenced via m6A modification in RCC, which may highlight m6A methylation‐based approach for RCC diagnosis and therapy.


  • Synthesis and evaluation of solanesol derivatives as novel potent synergistic agents

    by Jian-Hong Wang, Rui-Hong Gao, Ying Gan, Song-Qiang Xie, Chao-Jie Wang, Jin Zhao

    Novel solanesylpiperazinotriamines as well as their N-aryl-substituted analogs were synthesized starting from solanesol through a multistep procedure. Their structures were confirmed by IR, 1H NMR, MS, and elemental analysis. The preliminary results indicated that these novel derivatives were preferentially toxic against tumor cells, and at non-cytotoxic concentration, the synergistic effect of solanesyltriamines (3a and 3c) was even superior to that of N,N′-bis(3,4-dimethoxybenzyl)-N-solanesylethylenediamine. Interestingly, the cytotoxicity of solanesylpiperazinotriamine derivatives was markedly enhanced when conjugating with aryl pharmacophores (7–9).